Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder
NCT ID: NCT02508493
Last Updated: 2021-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2015-11-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To date, no measurement tool has been sufficiently validated and/or determined to be sensitive to the cognitive deficits in younger adults with MDD. Major limitations of available comprehensive psychometric tools include relative lack of availability, cost, lack of access to most healthcare providers, and above all else, the lengthy time to administer. Moreover, the need for a psychometrist to interpret the results adds to the complexity and the costliness of such an endeavor.
It is imperative that any tool recommended for clinical utility be aligned with the busy nature of a high-volume clinical practice. The ideal gold standard tool for assessing the presence of cognitive dysfunction in MDD in the clinical environment should include, but not be limited to, features such as good conceptual coverage of cognitive domains affected in MDD, good sensitivity and reliability, and it should be relatively uninfluenced by culture effects and practice effects. The tool would also need to be brief, easy to administer and interpret, and complement busy clinical practice.
This study is designed to validate a brief user-friendly tool capable of detecting deficit in cognitive performance among adults with MDD. Data will be gathered with the aim to determine whether the proposed tool identifies cognitive deficits in adults with MDD and differentiates the clinical MDD population from healthy controls.
It is anticipated that the THINC-it tool will be free of charge and downloadable from the THINC-it website for use in the primary care and specialty setting. The THINC-it tool will be accessible via computers/tablets, will take 20 minutes to self-administer in a clinical setting, and the performance results will be immediately available.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Major Depressive Disorder Population
100 Individuals with DSM-5-defined MDD, aged 18-65
THINC-it Tool
Digitalized cognitive test application administering the following cognitive test components:
* Digit Symbol Substitution Test (DSST)
* Choice Reaction Time (CRT)
* One-back working memory tool
* Trail Making Test B (TMT-B)
* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Pencil-and-paper Cognitive Tests
Pencil-and-paper versions of the following cognitive tests:
* Digit Symbol Substitution Test (DSST)
* Trail Making Test B (TMT-B)
* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
* Variant of Choice Reaction Time (CRT)
* Variant of the One-back working memory tool
Healthy Control Population
100 healthy controls matched on age, sex and years of education
THINC-it Tool
Digitalized cognitive test application administering the following cognitive test components:
* Digit Symbol Substitution Test (DSST)
* Choice Reaction Time (CRT)
* One-back working memory tool
* Trail Making Test B (TMT-B)
* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Pencil-and-paper Cognitive Tests
Pencil-and-paper versions of the following cognitive tests:
* Digit Symbol Substitution Test (DSST)
* Trail Making Test B (TMT-B)
* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
* Variant of Choice Reaction Time (CRT)
* Variant of the One-back working memory tool
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
THINC-it Tool
Digitalized cognitive test application administering the following cognitive test components:
* Digit Symbol Substitution Test (DSST)
* Choice Reaction Time (CRT)
* One-back working memory tool
* Trail Making Test B (TMT-B)
* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Pencil-and-paper Cognitive Tests
Pencil-and-paper versions of the following cognitive tests:
* Digit Symbol Substitution Test (DSST)
* Trail Making Test B (TMT-B)
* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
* Variant of Choice Reaction Time (CRT)
* Variant of the One-back working memory tool
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant is male or female between the ages of 18-65.
* The participant has received a diagnosis of a major depressive disorder (MDE) as per DSM-5 criteria.
* Current MDE is confirmed by the MINI for DSM-IV-TR.
* The participant is an outpatient at a psychiatric setting.
* The participant has a MADRS score equal to or greater than 22.
* The reported duration of current depressive episode is at least 3 months.
* The participant has been receiving a stable antidepressant dose for a minimum of 2 weeks prior to the study visit.
* At least one prior episode by history of depression validated by previous treatment (e.g. guidelines-informed pharmacotherapy and/or manual-based psychotherapy).
* Health Canada-approved antidepressant; add-on agents commensurate with Canadian (i.e. CANMAT) and American treatment-guidelines for MDD will be permitted.
* Enrollment in manual-based and/or supportive psychotherapy will be permitted.
* No current or past history of mental disorder as evidence by MINI or DSM-IV-TR.
* No first-degree relative with an established diagnosis by a healthcare provider of a mood or psychiatric disorder.
* No unstable medical disorders.
Exclusion Criteria
* Presence of comorbid psychiatric disorder other than MDD that is a focus of clinical concern as confirmed by the MINI for DSM-IV-TR.
* Medications approved for and/or employed off label for cognitive dysfunction (e.g. psychostimulants).
* Any medication for a general medical disorder that in the opinion of the investigator may affect cognitive function (e.g. corticosteroids, beta-blockers).
* Use of benzodiazepines within 12 hours of THINC-it tool administration.
* Consumption of alcohol within 8 hours of THINC-it tool administration.
* The patient has physical, cognitive, or language impairment of some severity as to adversely affect the validity of the data derived from neuropsychological tests.
* The patient is diagnosed with a reading disability or dyslexia.
* The patient cannot have a clinically significant learning disorder by history.
* The patient has received electroconvulsive therapy (ECT) in the last 6 months.
* The patient has a history of moderate or severe head trauma (e.g. loss of consciousness for over 1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system.
Healthy Controls:
* Any medication for a general medical disorder that in the opinion of the investigator may affect cognitive function (e.g. corticosteroids, beta-blockers).
* Consumption of alcohol within 8 hours of THINC-it tool administration.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Co-Principal Investigators: Dr. Roger S. McIntyre & Dr. John Harrison
UNKNOWN
Imperial College London
OTHER
Brain and Cognition Discovery Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roger McIntyre
Executive Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roger McIntyre
Role: PRINCIPAL_INVESTIGATOR
Brain and Cognition Discovery Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CRTCE/KJK Healthplex
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cha DS, Carmona N, Cha RH, Zhou AJ, Subramaniapillai M, Mansur RB, Lee Y, Lee JH, Lee J, Almatham F, Alageel A, Rosenblat JD, Shekotikhina M, Rong C, Harrison J, McIntyre RS. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity. Ann Clin Psychiatry. 2019 Feb;31(1):17-26.
Cha DS, Carmona NE, Rodrigues NB, Mansur RB, Lee Y, Subramaniapillai M, Phan L, Cha RH, Pan Z, Lee JH, Lee J, Almatham F, Alageel A, Rosenblat JD, Shekotikhina M, Rong C, Harrison J, McIntyre RS. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. J Affect Disord. 2018 Oct 1;238:228-232. doi: 10.1016/j.jad.2018.05.006. Epub 2018 Jun 1.
Carmona NE, Subramaniapillai M, Mansur RB, Cha DS, Lee Y, Fus D, McIntyre RS. Sex differences in the mediators of functional disability in Major Depressive Disorder. J Psychiatr Res. 2018 Jan;96:108-114. doi: 10.1016/j.jpsychires.2017.09.025. Epub 2017 Sep 30.
McIntyre RS, Best MW, Bowie CR, Carmona NE, Cha DS, Lee Y, Subramaniapillai M, Mansur RB, Barry H, Baune BT, Culpepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Wittchen HU, Harrison J. The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jul;78(7):873-881. doi: 10.4088/JCP.16m11329.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCDF-THINC.it
Identifier Type: -
Identifier Source: org_study_id